DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/03/3109-1151-1160$20.00
DMD 31:1151-1160, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, B. M.
Right arrow Articles by Porter, C. J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, B. M.
Right arrow Articles by Porter, C. J. H.

APPLICATION OF COMPARTMENTAL MODELING TO AN EXAMINATION OF IN VITRO INTESTINAL PERMEABILITY DATA: ASSESSING THE IMPACT OF TISSUE UPTAKE, P-GLYCOPROTEIN, AND CYP3A

Brendan M. Johnson, William N. Charman, and Christopher J. H. Porter

Department of Pharmaceutics, Victorian College of Pharmacy—Monash University, Parkville, Victoria, Australia

P-glycoprotein (P-gp)-mediated drug efflux and cytochrome P450 3A (CYP3A) metabolism within the enterocyte have been implicated as potential biochemical barriers to intestinal drug permeability. The current studies examined the in vitro intestinal permeability of verapamil, a common P-gp and CYP3A substrate, using both disappearance and appearance measurements, and investigated the possible impact of P-gp efflux on the intestinal extraction of verapamil. Bidirectional permeability and metabolism studies were conducted across rat jejunal tissue in side-by-side diffusion chambers and data were modeled using compartmental kinetics. Substantial tissue uptake of verapamil was evident in the in vitro model and resulted in a disappearance permeability coefficient that was approximately 10-fold greater than that determined from verapamil appearance in the receptor chamber. Polarization of the bidirectional transport of verapamil was evident due to P-gp efflux (efflux ratio of 2.5), and significant intestinal extraction of verapamil on passage across the tissue was observed (mucosal to serosal extraction ratio of 0.31 ± 0.04). Surprisingly, the selective P-gp inhibitor, valspodar (PSC833), had an insignificant impact on P-gp-mediated efflux of verapamil; however, selective CYP3A inhibition (afforded by midazolam) increased mucosal to serosal verapamil transport 1.6-fold, presumably through a reduction in intestinal metabolism. Using a four-compartment model, simulations of the impact of P-gp on the intestinal extraction ratio of verapamil demonstrated that for efflux to increase intestinal extraction, a nonlinear relationship must exist between the extent of drug metabolism and the extent of drug transport; the origin of this "nonlinearity" may include saturable drug metabolism, accumulation, and/or distribution.


Address correspondence to: Dr. Christopher J. H. Porter, Dept. of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Pde., Parkville, 3052, Victoria, Australia. E-mail: Chris.Porter{at}vcp.monash.edu.au




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
W. Zhang and L.-Y. Lim
Effects of Spice Constituents on P-Glycoprotein-Mediated Transport and CYP3A4-Mediated Metabolism in Vitro
Drug Metab. Dispos., July 1, 2008; 36(7): 1283 - 1290.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Nishimura, N. Amano, Y. Kubo, M. Ono, Y. Kato, H. Fujita, Y. Kimura, and A. Tsuji
Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey
Drug Metab. Dispos., August 1, 2007; 35(8): 1275 - 1284.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. H. Chang, C. J. Kochansky, and M. Shou
The Role of P-glycoprotein in the Bioactivation of Raloxifene
Drug Metab. Dispos., December 1, 2006; 34(12): 2073 - 2078.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Z. Turncliff, K. A. Hoffmaster, J. C. Kalvass, G. M. Pollack, and K. L. R. Brouwer
Hepatobiliary Disposition of a Drug/Metabolite Pair: Comprehensive Pharmacokinetic Modeling in Sandwich-Cultured Rat Hepatocytes
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 881 - 889.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.